Over 720 patients whose disease had progressed on one previous systemic therapy (cytokines, mTOR inhibitors, and VEGF inhibitors with the exception of axitinib and sorafenib) for RCC were randomized 1:1 to receive either axitinib or sorafenib. Here, MTOR is linked to renal cell carcinoma.